Charleston, SCNCT05036226Now EnrollingIRB Ready

Prostate Cancer Recurrent Clinical Trial in Charleston, SC

Access cutting-edge prostate cancer recurrent treatment through this clinical trial at a research site in Charleston. Study-provided care at no cost to qualified participants.

Sponsored by Medical University of South Carolina

Quick Self-Assessment

See if you qualify for this Charleston location

Preparing your pre-screening questions…

Expert Care in Charleston

Access prostate cancer recurrent specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related prostate cancer recurrent treatment provided free

Apply for This Charleston Location

Check if you qualify for this prostate cancer recurrent clinical trial in Charleston, SC

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Charleston

    Convenient for SC residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Charleston site if eligible
  4. 4Begin participation

About This Prostate Cancer Recurrent Study in Charleston

The purpose of this Phase I/II study is to determine the safety and effectiveness of up to 5 study drugs used together for the treatment of solid tumor cancers. The drugs are hydroxychloroquine, metformin, sirolimus, dasatinib and nelfinavir and are given orally.

Sponsor: Medical University of South Carolina

Who Can Participate

Inclusion Criteria

Patient must have advanced solid tumor cancer of any type (Phase I) or advanced prostate cancer (Phase II). Prostate cancer patients must have a PSA of at least 0.1 ng/mL.
Tissue diagnosis documented by pathology report, or clinic note attesting to same.
Measurable / evaluable tumor by RECIST, quantitative blood biomarker, or radionuclide imaging
Voluntary, signed and dated, Institutional Review Board (IRB) approved consent form in accordance with regulatory and institutional guidelines.
Documented progression of disease during treatment with one or more standard systemic regimens. Single or multiple regimens of chemotherapy, hormone suppression therapy, radiation therapy, surgery, immunotherapy, or adoptive cell therapy are allowed.
18 years of age or older.
ECOG performance status of 0-2.
Bilirubin ≤ 1.5 times upper limit of normal (ULN) and AST / ALT ≤ 3 times ULN. Subjects with Gilbert's syndrome may be included if the total bilirubin is \< 3 times ULN and the direct bilirubin is within normal limits.
Serum creatinine ≤ 1.5 times ULN.
Absolute neutrophil count (ANC) ≥ 1,000 cells / mm3
Platelet count ≥ 75,000 cells / mm3
Hemoglobin ≥ 9 g/ dL.
Fasting glucose ≤ 160 mg/dL or non-fasting glucose ≤ 200 mg/dL.
Urinalysis with no clinically significant abnormalities.
Adequately controlled blood pressure as determined by the treating investigator.
Subjects with the potential to produce children must agree to effective contraceptive method use during study participation.
Patients requiring narcotic analgesics must be on stable doses for at least 2 weeks prior to study entry.
Patients being considered for a dose level containing nelfinavir mesylate must discontinue any statin use within 48 hours of beginning study treatment.

Exclusion Criteria

New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia, or history of ischemia on ECG.
Underlying psychiatric disorder requiring hospitalization within the last two years.
Clinically significant neurological disorder (Parkinson's disease, dementia, multiple sclerosis), as determined by the enrolling investigator.
Active, uncontrolled bacterial, viral, or fungal infection, requiring systemic therapy.
Treatment with local or systemic radiation therapy, surgery, or investigational therapy within 28 days prior to registration.
Unwillingness or inability to comply with procedures required in this protocol.
Serious nonmalignant disease that could compromise protocol objectives in the opinion of the Investigator.
Patients who are receiving, coumadin, apixaban, argatroban or rivaroxaban.
Patients who are currently participating in any other clinical trial of an investigational product.
Any other mental incapacitation or psychiatric illness that would preclude study participation, as determined by the enrolling investigator.
Prisoners or patients who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness must not be enrolled into this study.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Charleston?

Yes, this clinical trial (NCT05036226) has an active research site in Charleston, SC that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Prostate Cancer Recurrent Treatment Options in Charleston, SC

If you're searching for prostate cancer recurrent treatment options in Charleston, SC, this clinical trial (NCT05036226) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Charleston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced prostate cancer recurrent specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all prostate cancer recurrent clinical trials near you to find additional studies recruiting in your area.

More Prostate Cancer Trials in Charleston, SC

See all prostate cancer clinical trials recruiting in Charleston — not just this study.

Browse Prostate Cancer Trials in Charleston →

Browse More Trials by Condition

Prostate Cancer TrialsAll Conditions →

Ready to Join in Charleston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Charleston, SC